A Weight-Loss Pill Without the Strings Attached

Eli Lilly's once-daily GLP-1 pill Foundayo wins FDA approval, offering needle-free obesity care from $25 a month

8 Apr 2026

The Food and Drug Administration approved Eli Lilly's once-daily weight-loss pill Foundayo on April 1, clearing the first small-molecule oral GLP-1 receptor agonist to reach American patients and broadening a market that has, until recently, been dominated by weekly injections. The drug, whose active ingredient is orforglipron, is approved for adults with obesity or overweight with at least one weight-related health condition.

Unlike Novo Nordisk's oral semaglutide, which must be taken on an empty stomach with limited water, Foundayo carries no food or water restrictions, a distinction Lilly has positioned as a meaningful advantage for patient adherence. The FDA cleared the drug 50 days after filing, under its Commissioner's National Priority Voucher program, making it the fastest approval of a new molecular entity since 2002. Novo Nordisk's oral Wegovy had received FDA approval in December 2025, giving that drug a head start in the oral GLP-1 market that Lilly is now entering.

The ATTAIN Phase III program enrolled more than 4,500 participants across two global trials. In the ATTAIN-1 trial, participants on the highest dose who completed treatment lost an average of 27.3 pounds, a 12.4% reduction in body weight, compared to 2.2 pounds with placebo. Across all participants regardless of trial completion, average weight loss was 25 pounds. The drug also reduced cardiovascular risk markers including cholesterol, triglycerides, and blood pressure. Gastrointestinal side effects were common, and the drug's label carries a boxed warning for thyroid C-cell tumors; it should not be used in patients with a personal or family history of medullary thyroid cancer.

Efficacy comparisons with oral Wegovy are complicated by the drugs' different mechanisms: orforglipron is a small molecule, while oral semaglutide is a peptide, and no head-to-head trials have been conducted. On pricing, Lilly has moved aggressively. Novo launched its Wegovy pill at a cash price of up to $299 a month, undercutting Lilly's originally announced range; Lilly has since lowered its self-pay price to a cap of $299 a month for patients who continuously renew prescriptions. Commercially insured patients pay as little as $25 per month with a savings card.

Lilly CEO David Ricks has noted that fewer than one in ten people who could benefit from a GLP-1 therapy are currently taking one, a gap the company attributes to access barriers and the complexity of existing options. Whether a pill at competitive price points meaningfully closes that gap, or whether gastrointestinal tolerability and the absence of cardiovascular outcome data limit uptake among higher-risk patients, remains to be seen as the drug moves from clinical trial to clinical practice.